~~<i id='5E5ACCD72D'><strike id='5E5ACCD72D'><tt id='5E5ACCD72D'><pre id='5E5ACCD72D'></pre></tt></strike></i>~~

Home» focus» focus

focus

author：hotspot 2025-08-15 12:36:36 Page View：36561

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Thousands protest mob assault of women who were paraded naked in remote Indian border state
Next article： The high cost of giving birth even with insurance

explore

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Novartis develops a rapidly manufactured CAR

RubyWallauforSTATNEWORLEANS—Forsomepatientssufferingwithcertainbloodcancers,CAR-Ttherapycanofferthet

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Maisha Meds is a PBM, but don't call it that

ZachariahKirimiisapharmacistwhousestheMaishaMedsapptohelpmanagehisinventoryandoffersubsidizedproduct